Journal article

Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine

Anna R Giuliano, Eduardo Lazcano-Ponce, Luisa Villa, Terry Nolan, Colin Marchant, David Radley, Greg Golm, Kathleen McCarroll, Jimmy Yu, Mark T Esser, Scott C Vuocolo, Eliav Barr

JOURNAL OF INFECTIOUS DISEASES | UNIV CHICAGO PRESS | Published : 2007

Abstract

BACKGROUND: The quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-particle vaccine was 95%-100% effective in preventing cervical and genital disease related to HPV-6, -11, -16, and -18. Vaccine efficacy is thought to be mediated by humoral immunity. Here, we analyze the effect of the baseline characteristics of subjects on vaccine-induced immune responses. METHODS: Immunogenicity data from 12,343 subjects 9-26 years old randomized to quadrivalent HPV vaccine or placebo in phase 2/3 studies were analyzed. Covariates examined were day 1 HPV serostatus, age, race/ethnicity, region of residence, lactation status, hormonal contraceptive usage, smoking status, Pap tes..

View full abstract

University of Melbourne Researchers